Study S000262

Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02920190
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: WITHDRAWN
Enrollment: 0
Start: 2020-09-01
Primary completion: 2021-09-01
Lead sponsor: University of Miami
Conditions: Monoclonal Gammopathies; Overweight; Obesity
Interventions: DRUG:Liraglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in Epicardial Fat Thickness [Baseline, 12 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.